氟芬那酸丁酯软膏治疗皮炎湿疹类皮肤病的临床疗效观察

氟芬那酸丁酯软膏(商品名：布特，上海同联集团研制生产)为非甾体类皮肤外用药物，具有抗炎、止痒、镇痛的作用．我们于2003年4-11月在门诊或住院患者中采用布特软膏治疗的46例皮炎湿疹类皮肤病，并与0．075％地塞米松软膏(皮炎平软膏)作对照，比较观察两种药物治疗皮炎湿疹类皮肤病的疗效，现将观察结果总结如下。     

湿疹及皮炎

20070776 婴儿脂溢性湿疹糠秕乌拉色菌带菌率调查分析；20070777 布特软膏与激素类制剂联合治疗湿疹皮炎30例临床观察；20070778 派瑞松治疗皮炎湿疹120例疗效与安全性观察；20070779 卡介菌多糖联合维D2果糖酸钙治疗皮炎湿疹疗效观察；20070780咪唑斯汀治疗皮炎湿疹类皮肤病疗效观察；[编按]     

氟芬那酸丁酯与糠酸莫米松乳膏联合治疗湿疹皮炎临床疗效观察

湿疹、面部皮炎是皮肤科门诊常见多发病,病情易反复。探寻安全有效的治疗方法尤为重要。我科于2009年4～12月,采用氟芬那酸丁酯软膏（商品名布特软膏,同联集团沈阳抗生素厂生产）与糠酸莫米松乳膏（商品名艾洛松软膏）联合应用治疗湿疹皮炎,取得了较满意的效果,现报告如下：     

氟芬那酸丁酯软膏联合恩肤霜治疗慢性皮炎湿疹

慢性湿疹和神经性皮炎都是常见的瘙痒性皮肤病,治愈困难且易复发。我们于2004年2月~2005年12月采用氟芬那酸丁酯软膏(商品名:布特,同联集团沈阳抗生素厂生产)和恩肤霜(丙酸氯倍他索软膏)外用治疗慢性皮炎湿疹112例,疗效满意,现将结果报道如下。临床资料112例患者均为我院皮肤科     

布特软膏治疗3种皮肤病临床疗效观察

布特软膏（沈阳同联集团生产）是一种外用非甾体类抗炎药，具有抗炎、镇痛等作用，临床用于治疗湿疹、皮炎等多种皮肤病，我科自2004年1～6月用布特软膏治疗3种皮肤病共90例，取得了较为满意的治疗效果，现报道如下。     

湿疹及皮炎

20042848　氟芬那酸丁酯软膏治疗皮炎湿疹类皮肤病的临床疗效观察/陆茂(三军大成都军医学院第47医院皮肤科)…//临床皮肤科杂志.-2004,33(4).-249实验组46例外用氟芬那酸丁酯软膏(布特,上海同联集团),对照组46例外用皮炎平软膏,均于每日早晚各1次外搽皮损,每周用药不超过20g,疗程21天,观察期禁用其他药物。结果两组痊愈率分别为26.1%,30.4%,有效率为63.0%,67.4%,差异均无显著性(P>0.05)。表1　(汤亚娥)20042849　派瑞松乳膏治疗皮炎湿疹30例/雷霞(三军大大坪医院皮肤科)…//皮肤病与性病.-2004,26(1).-26用派瑞松软膏外涂皮损处,2次/d,疗程…     

氟芬那酸丁酯软膏治疗外生殖器皮炎湿疹60例疗效观察

外生殖器皮炎湿疹是皮肤科常见多发疾病.由于外生殖器的特殊生理结构、腺体密集分泌旺盛、局部湿度较大、皮肤黏膜菲薄而容易诱发皮炎湿疹.临床治疗皮炎湿疹最常见的药物为皮质类型固醇类外用药,长期使用有免疫抑制、增加感染的缺点.我科于2006年4月-2007年5月,选用5%氟芬那酸丁酯软膏(商品名布特,同联集团沈阳抗菌素厂生产),对60例外生殖器皮炎湿疹患者进行治疗.报告如下.……     

氟芬那酸丁酯软膏治疗儿童皮炎湿疹类皮肤病临床观察

为观察氟芬那酸丁酯软膏(商品名:布特软膏,同联集团沈阳抗生素厂生产)治疗儿童湿疹,特应性皮炎及神经性皮炎的疗效及安全性,我们于2005年2月~10月,采用5%氟芬那酸丁酯软膏治疗儿童皮炎湿疹类皮肤病50例,现将结果报道如下。临床资料50例患者均来自本院门诊。男32例,女18例;年龄3个月~16岁;病程1个月~6年。湿疹36例,特应性皮炎8例,神经性皮炎6例。皮损发生于头面部的12例,四肢14例,躯干部8例,颈、肘部6例,躯干及四肢均受累者10例。入选标准:具有典型的湿疹皮炎的临床表现,皮损无渗出且非泛发。排除标准:对氟芬那酸丁酯及基质过敏者;1个月内接…     

氟芬那酸丁酯软膏治疗慢性湿疹50例临床疗效观察

氟芬那酸丁酯软膏(商品名：布特，同联集团沈阳抗生素厂)是一种外用非甾体类抗炎药，具有抗炎、镇痛等作用，临床上用于治疗皮炎、湿疹及带状疱疹等疾病，疗效好、不良反应小。2003年12月-2004年5月，我们采用布特治疗慢性湿疹50例．取得较为满意的疗效，现报告如下。     

布特软膏治疗儿童皮炎湿疹疗效观察

2004年1～6月我们采用布特软膏（同联集团沈阳抗生素厂生产）对105例儿童皮炎湿疹患者进行治疗。就疗效、安全性、耐受性进行观察评价，现报道如下。     

Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study

Tacrolimus is a macrolide immunosuppressant that has been demonstrated to inhibit T-lymphocyte activation without the side-effects of corticosteroids. The safety profile of tacrolimus makes it a promising therapeutic option for dermatitis. To evaluate and compare the therapeutic ability of tacrolimus 0.1% ointment and mometasone furoate 0.1% ointment in patients with chronic hand eczema and positive patch tests. Thirty adults with chronic hand eczema and positive patch test reaction to relevant contact allergens were treated with tacrolimus 0.1% ointment or mometasone furoate 0.1% ointment in a single-centre, randomized comparative study. The scores of the evaluated clinical parameters (erythema, infiltration, vesiculation, desquamation, presence of cracks and itching) did not differ between Groups A and B at any of the four time points (p>0.05).On the other hand, in both groups, a significant difference was detected in all parameters between baseline and Day 90 recorded values. Tacrolimus is a promising alternative therapy for contact dermatitis patients as it is effective from the first month of treatment, well tolerated and offers similar therapeutic results to topical corticosteroid therapy.     

青鹏软膏治疗儿童局限性皮炎湿疹68例

【摘要】 目的 观察青鹏软膏治疗局限性儿童皮炎湿疹的安全性。 方法 患有局限性皮炎湿疹类疾病的门诊患儿,其家长同意外用青鹏软膏者1周,每天2次,记录皮损评分不良反应。 结果 共入组68例,完成1周治疗61例,7例因皮损加重、疗效不明显或不相信此药物而未完成治疗。单纯应用青鹏治疗者总有效率81.4%。1例用药后出现刺激,未影响治疗。 结论 青鹏软膏治疗儿童皮炎湿疹有较好的疗效和安全性。     

Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment

BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid eczema, rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment. CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous. A variety of factors, such as vasoactive properties of tacrolimus, proliferation of Demodex due to local immunosuppression, and the occlusive properties of the ointment, may be involved in the observed phenomena. Future studies are needed to identify individual risk factors.     

Prognosis and atopic background of juvenile plantar dermatosis and gluteo-femoral eczema

A 10-year follow-up of patients with juvenile plantar dermatosis and gluteo-femoral eczema disclosed a worse prognosis than previously assumed, with a course in some cases protracted into adult age. The presence of atopy was established with a clinical point score system. It was found that 52% of the patients with juvenile plantar dermatosis and 80% of those with gluteo-femoral eczema were atopic. In many cases the childhood dermatitis was followed in adult age by a hand eczema. This was the case in 14% of the gluteo-femoral eczema patients, and no less than 26% of the juvenile plantar dermatitis patients.     

Eczema molluscatum in tacrolimus treated atopic dermatitis

Eczema molluscatum describes the occurrence of molluscum contagiosum virus infection in a patient with underlying atopic dermatitis. Novel, safe and effective treatment options in atopic dermatitis are the topical immunomodulators tacrolimus and pimecrolimus. One major advantage over corticosteroids is that they do not induce skin atrophy. Some physicians fear that topical immunomodulators may predispose patients to skin infections. We observed a patient with atopic dermatitis who developed eczema molluscatum during treatment with tacrolimus 0.1% ointment. After withdrawal of tacrolimus, the lesions resolved spontaneously over 3 weeks.     

湿疹和特应性皮炎皮损处细菌定植情况及药物联合治疗的分析

目的 探讨湿疹和特应性皮炎(AD)皮损处金黄色葡萄球菌(金葡菌)及其他细菌的定植情况,评价抗菌药物与糖皮质激素联合用药的疗效。方法 采用多中心、随机、双盲试验,在筛选日及治疗后第7、14和28天对皮损评分,并在皮损和非皮损处分离细菌。试验组外用抗菌药物和糖皮质激素,对照组外用基质和糖皮质激素。结果 共入选患者327例,湿疹208例,AD119例。湿疹皮损处细菌的阳性率为70.19%,金葡菌占47.26%;非皮损部位细菌阳性率为32.69%,金葡菌占27.94%。AD皮损处细菌阳性率为74.79%,金葡菌占79.78%;非皮损部位细菌阳性率为34.45%,金葡菌占80.49%。湿疹和AD皮损部位金葡菌的定植量均高于非皮损部位(P<0.01,P<0.05),细菌的定植量与皮损的严重程度呈正相关。两组患者治疗后总体疗效无明显差异(P>0.05),但湿疹临床症状评分指数>8分者及AD评分指数>7分者,在治疗的第7天,试验组与对照组的症状评分指数改善率存在显著差异(P<0.05),在治疗的第14天和第28天,两组差异均无显著性(P>0.05)。结论 湿疹和AD患者皮损部位细菌的检出率和金葡菌的带菌率均明显增高,说明金葡菌与湿疹皮炎的关系密切,早期联用抗菌药物可提高疗效。     

An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis

BACKGROUND: We identified 19 patients with facial atopic eczema who failed to respond to tacrolimus (FK506) ointment, although tacrolimus ointment has shown excellent benefit for the treatment of recalcitrant facial erythema in most patients with atopic dermatitis. OBJECTIVES: We attempted to determine the efficacy of an original lotion formulation of tacrolimus for facial atopic dermatitis resistant to tacrolimus ointment. PATIENTS/METHODS: Recalcitrant facial erythema of these 19 patients was treated with an original tacrolimus lotion preparation for 6 months. Patch testing with white petrolatum was performed in both the 19 patients and in 30 other atopic dermatitis patients who had experienced excellent results with tacrolimus ointment. RESULTS: Of the 19 resistant patients, those whose symptoms were greatly or moderately improved by the lotion were 95%, 89% and 89% after 2 weeks, 3 months and 6 months of treatment, respectively. Further, patch testing to petrolatum showed positive reactions in several (six of 19) patients, compared with none of 30 controls with atopic eczema that had responded to topical tacrolimus ointment. CONCLUSIONS: The tacrolimus lotion had a significant effect on the recalcitrant facial erythema in adult patients with atopic dermatitis who were resistant to tacrolimus ointment. We suggest that one reason for the unresponsiveness to tacrolimus ointment may be because of contact sensitivity to white petrolatum.     

Soak and smear: a standard technique revisited

BACKGROUND: Atopic dermatitis, nummular eczema, chronic hand dermatitis, palmar plantar psoriasis, and xerotic eczema are common inflammatory skin conditions. They may be refractory to conventional topical and even systemic treatment. Little evidence is available that demonstrates the benefits of aggressive topical treatment of patients with these disorders. OBJECTIVE: To describe a simple, inexpensive, effective topical treatment with an accompanying patient educational sheet. DESIGN: A retrospective study of 28 patients referred to a tertiary care center for refractory chronic pruritic eruptions. Intervention with a plain water 20-minute soak followed by smearing of mid-strength to high-strength corticosteroid ointment led to clearing or dramatic improvement. RESULTS: Objective and symptomatic improvement was obtained from aggressive topical treatment. It was well accepted in this group of referral patients. CONCLUSIONS: Hydration for 20 minutes before bedtime followed by ointment application to wet skin and alteration of cleansing habits is an effective method for caring for several common skin conditions. Prospective studies are needed to further validate these findings.     

317例斑贴试验结果分析

目的：探讨皮炎,湿疹类皮肤病接触性病因及发生规律。方法：用辨敏牌标准筛选斑贴试验试剂盒对患者做斑贴试验。结果：317例患者中阳性者218例,阳性率68．77％,其中湿疹,皮炎,荨麻疹的阳性率明显高于其他病种,痤疮,丘疹性荨麻疹,唇部色素沉着亦有阳性结果。结论：斑贴试验对皮炎,湿疹类皮肤病有确定的指导,防治意义,对某些不典型的皮肤病,如寻常痤疮,丘疹性荨麻疹,唇部色素沉着等应做斑试,以排除接触过敏的可能。     

The use of sibicort in the combined therapy of patients with eczema, neurodermatitis and allergic dermatitis

The authors assess the clinical efficacy of sibicort, and ointment manufactured by Orion, Finland, used in therapy of patients suffering from neurodermatitis, eczema, and allergic dermatitis. Pathogenetic treatment combined with sibicort has been administered to 64 patients with disseminated true eczema, 115 ones with diffuse neurodermatitis, and 20 ones with allergic dermatitis. The ointment has been applied to and a little bit rubbed in the foci of lesions twice a day. Sibicort has proved to be a highly effective external drug for the treatment of allergic itching dermatoses. Both immediate and late results have been the best in neurodermatitis patients. No side effects or complications associated with this ointment application have been observed; the drug has been well tolerated.